Serum regulates cortisol bioactivity by corticosteroid-binding globulin dependent and independent mechanisms, as revealed by combined bioassay and physicochemical assay approaches.
AffiliationDepartment of Endocrinology, Christie Hospital, Manchester, UK Endocrine Sciences Research Group, University of Manchester, Manchester, UK.
MetadataShow full item record
AbstractContext: Corticosteroid-binding globulin (CBG) is the principal carrier of natural glucocorticoids in the circulation and we hypothesized that it modulates glucocorticoid bioactivity. Alterations in CBG, the presence of non-cortisol, naturally occurring glucocorticoids and the use of potent, synthetic glucocorticoids, all make it difficult to assess adrenal activity in-vivo; these problems can be addressed by a glucocorticoid bioassay. Design and subjects: A bioassay was developed for serum glucocorticoid bioactivity (GBA) and a physicochemical ultrafiltration-liquid chromatography-tandem mass spectrometry assay for free serum cortisol (FreeF). We studied individuals homozygous and heterozygous for a non-functioning CBG variant (CBG G237V) and healthy controls. Results: FreeF concentrations were similar in healthy controls, and those with absent functional CBG, but surprisingly we found low GBA in CBG null individuals. This may suggest that CBG delivers cortisol to target cells. However, further experiments revealed that dilution of serum in the bioassay caused release of cortisol from CBG, resulting in elevated GBA measurements in all but the CBG G237V homozygotes. Furthermore, we identified a specific and potent inhibitory effect of high concentration serum on glucocorticoid sensitivity of the recipient cells used in the bioassay. Analysis of inflammatory synovial fluid, a filtrate of serum with lower CBG concentration, revealed elevated free cortisol compared to non-inflammatory synovial fluid, a change not attributable to interconversion between cortisol and cortisone. Conclusions: Our findings reveal that dilution of CBG enhances cortisol release, and so bioactivity, and also that serum potently induces glucocorticoid resistance in target cells.
CitationSerum regulates cortisol bioactivity by corticosteroid-binding globulin dependent and independent mechanisms, as revealed by combined bioassay and physicochemical assay approaches. 2011, 75(1) : 31-38 Clin Endocrinol
- Novel human corticosteroid-binding globulin variant with low cortisol-binding affinity.
- Authors: Emptoz-Bonneton A, Cousin P, Seguchi K, Avvakumov GV, Bully C, Hammond GL, Pugeat M
- Issue date: 2000 Jan
- Corticosteroid-binding globulin regulates cortisol pharmacokinetics.
- Authors: Perogamvros I, Aarons L, Miller AG, Trainer PJ, Ray DW
- Issue date: 2011 Jan
- Novel corticosteroid-binding globulin variant that lacks steroid binding activity.
- Authors: Perogamvros I, Underhill C, Henley DE, Hadfield KD, Newman WG, Ray DW, Lightman SL, Hammond GL, Trainer PJ
- Issue date: 2010 Oct
- Salivary cortisone is a potential biomarker for serum free cortisol.
- Authors: Perogamvros I, Keevil BG, Ray DW, Trainer PJ
- Issue date: 2010 Nov
- Corticosteroid-binding globulin: modulating mechanisms of bioavailability of cortisol and its clinical implications.
- Authors: Bae YJ, Kratzsch J
- Issue date: 2015 Oct